SNORA69 is up-regulated in the lateral habenula of individuals with major depressive disorder

Rixing Lin,Haruka Mitsuhashi,Laura M. Fiori,Ryan Denniston,El Cherif Ibrahim,Catherine Belzung,Naguib Mechawar,Gustavo Turecki
DOI: https://doi.org/10.1038/s41598-024-58278-2
IF: 4.6
2024-04-14
Scientific Reports
Abstract:Major depressive disorder (MDD) is a complex and potentially debilitating illness whose etiology and pathology remains unclear. Non-coding RNAs have been implicated in MDD, where they display differential expression in the brain and the periphery. In this study, we quantified small nucleolar RNA (snoRNA) expression by small RNA sequencing in the lateral habenula (LHb) of individuals with MDD (n = 15) and psychiatrically-healthy controls (n = 15). We uncovered five snoRNAs that exhibited differential expression between MDD and controls (FDR < 0.01). Specifically, SNORA69 showed increased expression in MDD and was technically validated via RT-qPCR. We further investigated the expression of Snora69 in the LHb and peripheral blood of an unpredicted chronic mild stress (UCMS) mouse model of depression. Snora69 was specifically up-regulated in mice that underwent the UCMS paradigm. SNORA69 is known to guide pseudouridylation onto 5.8S and 18S rRNAs. We quantified the relative abundance of pseudouridines on 5.8S and 18S rRNA in human post-mortem LHb samples and found increased abundance of pseudouridines in the MDD group. Overall, our findings indicate the importance of brain snoRNAs in the pathology of MDD. Future studies characterizing SNORA69's role in MDD pathology is warranted.
multidisciplinary sciences
What problem does this paper attempt to address?
The paper aims to explore the differential expression of small nucleolar RNAs (snoRNAs) in Major Depressive Disorder (MDD) and its potential mechanisms. Specifically, the researchers analyzed the lateral habenula (LHb) tissue samples from MDD patients and mentally healthy control groups using small RNA sequencing technology. They found that five snoRNAs were significantly differentially expressed between the two groups, with SNORA69 being significantly upregulated in MDD patients. Additionally, the study validated the expression of SNORA69 in an unpredictable chronic mild stress (UCMS) mouse model and investigated its relationship with pseudouridylation modifications in 5.8S and 18S rRNA. The results suggest that SNORA69 may play an important role in the pathological process of MDD, but its specific mechanism of action requires further research.